Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2808 - Usability testing of EirV3-a computer-based tool for patient reported outcome measures in cancer

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Hilde Krogstad

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

H. Krogstad1, S.M. Sundt-Hansen2, M.J. Hjermstad3, L.Å. Hågensen4, S. Kaasa3, J.H. Loge5, S.X. Raj1, A. Steinsbekk6, K. Sand1

Author affiliations

  • 1 European Palliative Care Research Centre (prc) And Department Of Clinical And Molecular Medicine, Faculty Of Medicine And Health Sciences, And Cancer Clinic, Norwegian University of Science and Technology and St.Olavs Hospital, Trondheim University Hospital, NO-7491 - Trondheim/NO
  • 2 Department Of Medicine, St.Olavs hospital, Trondheim University Hospital, NO-7491 - Trondheim/NO
  • 3 European Palliative Care Research Centre, Institute Of Clinical Medicine And Department Of Oncology, University of Oslo and Oslo University Hospital, 424 - Oslo/NO
  • 4 Coordination Unit Orkdal Region, Orkdal Region, 7300 - Orkanger/NO
  • 5 Institute Of Basic Medical Sciences, Faculty Of Medicine And Department Of Oncology, University of Oslo and Oslo University Hospital, 424 - Oslo/NO
  • 6 Department Of Public Health And Nursing, Faculty Of Medicine And Health Sciences, Norwegian University of Science and Technology, 7491 - Trondheim/NO
More

Resources

Abstract 2808

Background

Eir Version 3 (V3) is an electronic tool for registration administration of patient reported outcome measures (Eir-Patient) that immediately presents patient scores on the physiciańs computer (Eir-Doctor). Perceived usability is an important determinant for successful implementation.The objective was to assess the number, type, and severity of usability issues of the Eir-Patient and Eir-Doctor modules respectively, when used by cancer patients and physicians in three different settings: 1) outpatient clinics, 2) at home, and 3) at the general practitioner’s office.

Methods

A usability evaluation using observations, think-aloud sessions, individual and focus group interviews in patients and their physicians was conducted. Identified usability issues were graded on a severity scale from 1 (irritant) to 4 (unusable).

Results

Overall, 73 Eir registrations were performed by 37 patients, and used by 17 physicians in clinical consultations. All patients were able to complete the Eir-Patient symptom registration, which was perceived easy. Seventy-two usability issues were identified. None of them were graded as unusable. 62% of the identified usability issues in Eir-Patient were graded as irritant (grade 1), 18% and 20% as moderate or severe (grade 2-3), none as unusable. For the Eir-Doctor module, 46% of the identified usability issues were graded as irritant, 36% as moderate and 18% as severe. Observations of physician consultations showed that Eir-Doctor was intuitive and easy to use.

Conclusions

Patients and physicians found EirV3 easy to use. Results indicate that EirV3 is usable for a heterogeneous population of cancer patients, in different settings. In the subsequent Eir-version, issues in the severe and moderate categories have been changed, to optimize the usability and feasibility of using real time PROMs in clinical practice.

Clinical trial identification

Legal entity responsible for the study

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, NTNU.

Funding

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, and Regional Research Funds in Norway, Mid-Norway.

Editorial Acknowledgement

Disclosure

S. Kaasa, J.H. Loge: Eir Solutions AS was established in 2015 with Kaasa, Loge and NTNU Technology Transfer AS/Andersen as shareholders. No income, dividend or financial benefits are related to the work presented here, nor in relation to Eir in any way. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.